ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
The E2F1/SBK1 axis activates the Notch signaling pathway to accelerate the malignant progression of breast cancer.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Focused ultrasound for cellular mechanoactivation and nanomedicine delivery in cancer.Biomedical microdevices · 2026Review
- SIRT1 induces FOXO1/autophagy/NCOA4-induced ferroptosis and accelerates the progression of cerebral infarction by inhibiting the E2F1/NOTCH-1/YAP signaling pathway.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is one of the leading causes of cancer mortality in women, and its incidence continues to increase worldwide. It has been confirmed that E2F transcription factor 1 (E2F1) is associated with increased malignancy and poor prognosis in breast cancer tumors. Although SH3 domain-binding kinase 1 (SBK1) expression is upregulated in various cancers, its function in breast cancer has not been fully investigated. Therefore, it is of great significance to explore whether E2F1 and SBK1 cooperate to regulate the progression of breast cancer. UALCAN and GEPIA websites were used to predict the expression of SBK1 in different tumors, especially breast cancer tumors. Real-time quantitative PCR (RT-qPCR) and Western blotting (WB) assays were employed to quantify the levels of mRNA and proteins, respectively. Cell proliferation, apoptosis, migration, and invasion were conducted using 5-ethynyl-2'-deoxyuridine (EdU) assay, flow cytometry, and Transwell assay. Commercial kits were applied to measure the lactate and glucose levels. We constructed a mouse xenograft model to verify the effect of SBK1 on breast cancer in vivo. Interrelation between E2F1 and SBK1 was identified by Chromatin Immunoprecipitation (ChIP) and dual-luciferase labeling assay. Through bioinformatics analysis, WB, and RT-qPCR experiments, it was observed that both SBK1 and E2F1 were significantly overexpressed in breast cancer tissues and cells. Silencing SBK1 inhibited the malignant proliferation, migration, invasion, glycolysis, and the macrophage M2 polarization, but promoted apoptosis of breast cancer cells. Specifically, silencing SBK1 inhibited the growth of subcutaneously transplanted tumors in mice. Additionally, E2F1 was confirmed to positively regulate SBK1, and the anticancer effect of E2F1 knockdown was rescued by SBK1 overexpression. Meanwhile, the expression of the Notch signaling pathway-related proteins was downregulated after E2F1 knockdown and could also be restored by SBK1 overexpression. This study elucidated the mechanism of SBK1/E2F1 involved in the progression of breast cancer and provided a new target for the treatment of breast cancer.
Indexed as
Identifiers
40423801What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.